By admin 
CureSearch for Children’s Cancer, a leading national non-profit organization dedicated to accelerating the development of new treatments for pediatric malignancies, has officially announced the appointment of Osama Alsaleh to its Board of Directors. The addition of Alsaleh, a prominent figure in the global healthcare innovation and venture capital landscape, marks a strategic effort by the organization to bridge the gap between traditional research funding and the high-tech, fast-paced world of private investment and technology-driven healthcare solutions.
As the current Head of Partnerships at Plug and Play Health—one of the world’s most active venture capital firms and a premier global innovation platform—Alsaleh brings a sophisticated understanding of how early-stage startups and disruptive technologies can be scaled to meet critical medical needs. His appointment comes at a pivotal moment for CureSearch, as the organization increasingly focuses on "venture philanthropy" models to overcome the "valley of death" in drug development, where promising laboratory research often stalls due to a lack of funding for clinical trials.
A Career Defined by Strategic Innovation and Health Equity
Osama Alsaleh’s professional trajectory has been characterized by a consistent focus on the intersection of healthcare IT, regulatory compliance, and global health initiatives. Before joining Plug and Play Health, Alsaleh held senior roles at Oracle Health (formerly Cerner Corporation), where he was instrumental in shaping the company’s approach to modernizing healthcare delivery.
One of his most significant contributions during his tenure at Oracle Health was the spearheading of the Health Equity team. In this capacity, he developed transformative strategies aimed at addressing social determinants of health (SDOH), accessibility, and digital inclusion. His work ensured that technological advancements in healthcare reached underserved populations, a perspective that is increasingly vital in pediatric oncology, where access to specialized care and clinical trials can vary significantly based on socioeconomic and geographic factors.
Furthermore, Alsaleh’s background in philanthropy is deeply rooted in his experience with the Oracle Charitable Foundation Clinical Decision Committee. During his time there, he contributed to the evaluation and allocation of more than $42 million in healthcare grants. This experience provided him with a rigorous framework for assessing the viability and impact of medical research projects, a skill set that aligns directly with CureSearch’s mission to fund only the most promising research with the highest potential for clinical application.
The Chronology of a Global Healthcare Advocate
The professional journey of Osama Alsaleh reflects a broad commitment to systemic improvement within the healthcare sector. His career path provides a blueprint for how cross-sector collaboration can drive progress in complex medical fields:
- Early Career and Global Health Foundations: Alsaleh’s early work involved collaboration with major international bodies, including the World Bank Group and the World Health Organization (WHO). These roles provided him with a macro-level understanding of global health infrastructure and the importance of sustainable, scalable health solutions.
- Technological Integration at Cerner and Oracle: Transitioning into the private sector, he spent years at Cerner (later acquired by Oracle), focusing on healthcare IT and strategic partnerships. His work here centered on how data and technology could improve patient outcomes and streamline clinical workflows.
- Regulatory and Crisis Response: Alsaleh served as a critical advisor on quality reporting measures and collaborated with United States federal agencies. His resume includes work with the Centers for Medicare & Medicaid Services (CMS) initiatives, the White House COVID-19 Taskforce, and the U.S. State Department. These roles highlight his ability to navigate the complex regulatory environments that govern drug approval and healthcare delivery.
- Venture Capital Leadership: In his current role at Plug and Play Health, Alsaleh oversees a vast ecosystem of startups, corporate partners, and investors. He is responsible for identifying the next generation of healthcare breakthroughs and fostering the collaborations necessary to bring them to market.
Addressing the Funding Disparity in Pediatric Oncology
The appointment of a venture capital expert to the CureSearch board addresses a stark reality in the oncology landscape: pediatric cancer research is significantly underfunded compared to adult cancers. According to data from the National Cancer Institute (NCI), while cancer is the leading cause of death by disease for children in the United States, only about 4% of federal funding for cancer research is specifically directed toward pediatric-specific studies.
The disparity is even more pronounced in the private sector. Traditional venture capital firms often view pediatric oncology as a "small market," making it difficult for biotech startups focusing on childhood cancers to secure the necessary Series A and Series B funding. Because the patient population is smaller than that of adult lung, breast, or prostate cancer, the perceived Return on Investment (ROI) is often lower, leading to what many in the field call "orphan disease" neglect.
By bringing Alsaleh into its leadership fold, CureSearch aims to leverage his network to change this narrative. His expertise allows the organization to better pitch pediatric research as a viable and necessary frontier for innovation, potentially attracting corporate venture arms and impact investors who have previously overlooked the space.
Perspectives from CureSearch Leadership
The leadership at CureSearch has expressed high expectations for the impact Alsaleh will have on the organization’s strategic direction. Jared Brancazio, Chair of CureSearch’s Board of Directors, emphasized the unique value proposition Alsaleh brings to the table.
"Osama brings a unique and highly valuable perspective to CureSearch," Brancazio stated. "His ability to connect innovation, investment, and healthcare will help expand our reach and unlock new opportunities to advance critical research for children with cancer. We are excited to have him join the board at this important time for our organization."
Alsaleh himself has identified the systemic gaps he hopes to close. "Throughout my work, I have consistently observed that innovations focused on pediatrics, particularly pediatric oncology, remain significantly underfunded and underrepresented within mainstream venture capital and innovation ecosystems," Alsaleh said. "By leveraging my network across venture capital, startups, healthcare institutions, and technology companies, I aim to help attract new technologies, strategic partners, and resources that can accelerate progress toward cures for children with cancer."
Broader Implications for the Future of Pediatric Research
The inclusion of a venture capital leader on a prominent non-profit board signals a broader shift in how medical research is being conducted and funded in the 21st century. This "venture philanthropy" model operates on several key principles that Alsaleh is uniquely qualified to oversee:
- Strategic De-risking: By using donor funds to support early-stage clinical trials, CureSearch "de-risks" the science. Once a treatment shows efficacy in early human trials, it becomes much more attractive to the private investors and pharmaceutical companies in Alsaleh’s network.
- Technological Integration: The use of Artificial Intelligence (AI) and machine learning in drug discovery is a major trend in the VC world. Alsaleh’s background at Oracle and Plug and Play suggests that CureSearch may look to incorporate more data-driven approaches to identify potential therapeutic targets.
- Global Collaboration: Pediatric cancer is a global challenge. Alsaleh’s experience with the WHO and the World Bank aligns with the need for international clinical trials, which are often necessary in pediatrics to achieve a statistically significant sample size of patients.
- Health Equity in Innovation: As therapies become more advanced—such as CAR-T cell therapy or personalized genomic medicine—there is a risk that they will only be available to the wealthiest patients. Alsaleh’s previous work on health equity ensures that the board will remain focused on making new treatments accessible to all children, regardless of their background.
About CureSearch for Children’s Cancer
CureSearch for Children’s Cancer is a national non-profit foundation that accelerates the search for cures for the 15,000 children diagnosed with cancer each year in the United States. Unlike organizations that focus solely on patient support or general awareness, CureSearch is specifically focused on the "bench-to-bedside" pipeline.
The organization’s strategy involves funding high-impact research at every stage of the development process, from initial discovery in the lab to Phase I and Phase II clinical trials. Through its "Impact Series" and "Catapult Awards," CureSearch has established a track record of identifying the most promising research and providing the financial and strategic support necessary to move those treatments closer to the children who need them.
With the appointment of Osama Alsaleh, CureSearch reinforces its commitment to a modern, aggressive, and collaborative approach to ending childhood cancer. His presence on the board is expected to foster a new era of strategic partnerships that will ultimately lead to more survivors and a higher quality of life for children battling the disease.
